Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Scentia Pharmaceuticals
Shanghai, Shanghai, Chinascientiapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Scientia Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology. The company leverages its expertise in structure-based drug design to target key drivers of cancer, such as FGFR, EGFR, and ALK. Its lead candidate, SC-0062, is a potent and selective pan-FGFR inhibitor currently being evaluated in Phase 1/2 clinical trials for patients with advanced solid tumors harboring FGFR alterations. Scientia operates with a dual presence in Shanghai, China, and Exton, Pennsylvania, aiming to address significant unmet medical needs in global markets.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Scentia Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scentia Pharmaceuticals.